Skip to main content

Contract Development and Manufacturing Organization Market worth USD 278.98 Billion by 2026; Increasing Demand for Pharmaceutical Products Will Aid Growth, says Fortune Business Insights™

Pune, March 24, 2020 (GLOBE NEWSWIRE) — The global contract development and manufacturing organization market size is projected to reach USD 278.98 billion by the end of 2026. Mergers and acquisitions are a growing trend among major companies across the world. According to a report published by Fortune Business Insights, titled “Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Industry Analysis, By Service {By CMO (API, Finished Product {Solid Dosage Forms, Injectables, and Others}, and Packaging)} {By CRO (Discovery, Preclinical, Clinical Trial, and Laboratory Services)} and Regional Forecast, 2019-2026,” the market was worth USD 130.80 billion in 2018 and will exhibit a CAGR of 10.0% during the forecast period, 2019-2026.
For more information in the analysis of this report, visit:
https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502
The contract development and manufacturing organization market is segmented on the basis of factors such as service and geographies. The report provides forecast values for the market for the period of 2019-2026. The factual figures have been obtained through trusted sources. Moreover, these predictions are made on the basis of extensive research analysis methods, coupled with the opinions of experienced market research professionals. The report highlights the latest product launches and labels major innovations in the market. In addition to this, it states the impact of these products on the growth of the market. The competitive landscape has been discussed in detail and predictions are made with respect to leading companies and products in the coming years.Product Overview:A contract development and manufacturing organization (CDMO) helps healthcare companies for the development of drugs. It is involved in the overall process, right from the clinical trials till the commercialization and distribution of the drugs. The complexities in therapies and lack of in-house manufacturing capabilities will have a positive impact on the growth of the market in the coming years. The high investment in CDMOs will bode well for the overall market in the coming years. Moreover, the increasing number of strategic mergers and collaborations will contribute to the growth of the market. The use of advanced technologies in drug development processes will emerge in favor of the companies operating in the market.Accounting to the huge potential held by CDMOs, several companies are looking to invest more in the development of newer products. The huge investments have yielded a few exceptional products in recent years. In May 2019, Recipharm AB announced the launch of a fully integrated service platform for inhalation products. This will include the early stages of the products including the pre-clinical trials to the commercialization of the products. Recipharm’s latest product will generate huge sales and subsequently high revenues for the company. This will not just benefit the company, but will have a positive impact on the growth of the overall market in the coming years.Asia Pacific to Register Highest CAGR; Increasing Company Collaborations Will Aid Growth of the Regional MarketThe report analyses the ongoing CDMO market trends across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among these regions, the market in Asia Pacific will register the highest CAGR in the coming years driven by the increasing number of company collaborations and mergers in several countries across the world. The market in North America is projected to emerge dominant in the coming years, owing to the presence of several well-established companies. As of 2018, the market in North America was worth USD 48.72 billion in 2018 and this value is projected to increase further in the coming years.List of key companies profiled in the CDMO Market Research Report are report:Catalent, IncBaxterVetterRecipharm ABAlbany Molecular Research Inc. (AMRI)Thermo Fisher Scientific Inc. (Patheon)UnitherDPT LABORATORIES LTD.NextPharma TechnologiesOthersIndustry Developments:February 2019: Jubilant Biosys collaborated with Sanofi to develop small molecule inhibitors for in the CNS therapeutic area.
Have Any Query? Ask Our Experts:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502

Detailed Table of Content:
1.      Introduction
        1.1.   Research Scope
        1.2.   Market Segmentation
        1.3.   Research Methodology
        1.4.   Definitions and Assumptions
2.      Executive Summary
3.      Market Dynamics
         3.1.   Market Trends
         3.2.   Market Drivers
         3.3.   Market Restraints
         3.4.   Market Opportunities
4.      Key Insights
         4.1.   Key Industry Developments (Mergers, Acquisitions, & Partnerships,)
         4.2.   The Regulatory Scenario for key countries/Regions
         4.3.   Key Market Trends
         4.4.   Key Services Mapping by Leading Players
5.      Global Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2015-2026
         5.1.   Key Findings / Summary
         5.2.   Market Analysis, Insights and Forecast – By Service
                  5.2.1. CMO
                            5.2.1.1. API Manufacturing
                            5.2.1.2.  Finished Product Manufacturing
                                         5.2.1.2.1.   Solid Dosage Forms
                                         5.2.1.2.2.    Injectables
                                         5.2.1.2.3.    Others (Semisolids/liquids, Powder)
                            5.2.1.3.   Packaging
                   5.2.2. CRO
                            5.2.2.1.  Discovery
                            5.2.2.2.  Preclinical
                            5.2.2.3.  Clinical
                            5.2.2.4.  Laboratory Services
5.3.   Market Analysis, Insights and Forecast – By Region
         5.3.1. North America
         5.3.2. Europe
         5.3.3. Asia Pacific
         5.3.4. Rest of the World
TOC Continued….!
Contract Research Organization (CRO) Services Market Size, Share and Global Trend By Service Type (Discovery, Pre-Clinical, Clinical, Laboratory Services), By Application (Oncology, Cardiology, Infectious Disease, Metabolic Disorders), By End User(Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes) and Geography Forecast till 2026Clinical Laboratory Services Market Size, Share and Global Trend By Laboratory Type (Speciality Clinical Laboratory, Integrated Clinical Laboratory), By Ownership (Hospital owned clinical laboratory, Standalone clinical laboratory, Others), By End User (Hospitals, Clinics, Research Centers, Others), and Geography Forecast till 2026Clinical Chemistry Market Size, Share and Global Trend By Product Type (Analyzers, Reagents & Consumables), By Application (General Chemistry Test, Liver Function Test, Kidney Function Test, Urinalysis, Electrolyte Panel, Lipid Profile, Specialty Chemical Test, Others), By End User (Hospitals, Diagnostic/Pathology Centers, Ambulatory Surgery Centers (ASC), Others), and Geography Forecast till 2026Drug Discovery Informatics Market Size, Share & Industry Analysis, By Service Type (In-house, Outsourced), By Modality (Cloud-based Systems, In-campus Platform), By Application (Data Sequencing, Molecular Docking, Identification and Validation Informatics, Target Data Analysis, Others), By End User (Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Others) and Regional Forecast, 2019-2026Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026
Influenza Medication Market Size, Share & Industry Analysis, By Treatment (Baloxavir marboxil, Oseltamivir phosphate, Others), By Influenza Type (Influenza A, Influenza B), By Route of Administration (Oral, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026
Telemedicine Market Size, Share & Industry Analysis By Type (Products, Services), By Application (Teleradiology, Telepathology, Teledermatology, Telepsychiatry, Telecardiology, Others), By Modality (Store-and-forward (Asynchronous), Real-time (Synchronous), Others), By End User (Healthcare Facilities, Homecare), and Regional Forecast 2019-2026
Telehealth Market Size, Share and Industry Analysis By Type (Products, Services), By Application (Telemedicine, Patient Monitoring, Continuous Medical Education, Others), By Modality (Store-and-forward (Asynchronous), Real-time (Synchronous), Remote Patient Monitoring), By End User (Healthcare Facilities, Homecare, Others), and Geography Forecast, 2019 – 2026
Injectable Drug Delivery Market Size, Share and Industry Analysis By Device Type (Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors, Others), By Application (Autoimmune Disorders, Diabetes, Pain Management, Aesthetic Treatments, Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, Others), By End-User (Hospitals, Home Care Settings, Clinics, Others), and Regional Forecast 2019-2026
Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 – 2026
Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2019-2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/contract-development-and-manufacturing-organization-cdmo-market-9673

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.